Objectives: To characterize antifactor Xa peak levels as therapeutic, subtherapeutic, or supratherapeutic, in patients with renal impairment who are receiving renally adjusted therapeutic doses of enoxaparin and to assess the correlation between Anti-Xa with renal function in these patients.